BioInvent International
Develops novel, first-in-class immuno-modulatory antibodies for cancer therapy.
BINV | ST
Overview
Corporate Details
- ISIN(s):
- SE0015244520
- LEI:
- 549300E7QRHEF2IJUY10
- Country:
- Sweden
- Address:
- C/O BioInvent International Aktiebolag, 223 70 Lund
- Website:
- https://www.bioinvent.com/en
- Sector:
- Manufacturing
Description
BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-08 14:00 |
BioInvent presenterar imponerande responsdata från den pågående fas 2a-studien …
|
Swedish | 86.2 KB | ||
| 2025-12-08 14:00 |
BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Trip…
|
English | 86.3 KB | ||
| 2025-12-07 14:00 |
BioInvent Presents Promising Early Phase 2a BI-1808 Monotherapy Data in CTCL at…
|
English | 86.2 KB | ||
| 2025-12-07 14:00 |
BioInvent presenterar lovande tidiga fas 2a-data på ASH 2025 för BI-1808 som mo…
|
Swedish | 86.7 KB | ||
| 2025-11-03 15:00 |
BioInvent presenterar uppdaterade fas 2a monoterapidata på ASH 2025 gällande BI…
|
Swedish | 83.1 KB | ||
| 2025-11-03 15:00 |
BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combina…
|
English | 81.9 KB | ||
| 2025-11-03 15:00 |
BioInvent to Present Updated Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2…
|
English | 82.2 KB | ||
| 2025-11-03 15:00 |
BioInvent kommer att presentera tidiga fas 2a-data på ASH 2025 från den pågåend…
|
Swedish | 81.9 KB | ||
| 2025-10-29 08:00 | Swedish | 2.5 MB | |||
| 2025-10-29 08:00 | English | 2.4 MB | |||
| 2025-09-02 10:10 |
BioInvent Announces Board of Directors Update
|
English | 67.9 KB | ||
| 2025-09-02 10:10 |
BioInvent offentliggör förändring i styrelsen
|
Swedish | 67.3 KB | ||
| 2025-08-26 08:30 | Swedish | 3.1 MB | |||
| 2025-08-26 08:30 | English | 3.0 MB | |||
| 2025-08-26 08:29 |
BioInvent Announces Strategic Changes in Portfolio to Accelerate Lead Clinical …
|
English | 82.3 KB |
Automate Your Workflow. Get a real-time feed of all BioInvent International filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioInvent International
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioInvent International via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-09 | Erik Esveld | Other | Buy | 4,000 | 70,960.00 SEK |
| 2023-06-30 | Sylvie Ryckebusch | Other | Buy | 5,000 | 7,890.00 EUR |
| 2022-11-16 | Dharminder Chahal | Other | Buy | 10,000 | 352,500.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 3,262 | 109,798.92 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 800 | 27,200.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 750 | 25,425.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 611 | 20,700.68 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 530 | 17,193.20 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 500 | 16,800.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 400 | 13,712.00 SEK |
Peer Companies
